The present invention provides a powder formulation containing glucagon or a glucagon analog for nasal administration, useful in the treatment of hypoglycemia, and in particular the treatment of severe hypoglycemia. The present invention also provides a method of making this powder formulation, and to devices and methods for using the powder formulation.

The present invention provides a powder formulation containing glucagon or a glucagon analog for nasal administration, useful in the treatment of hypoglycemia, and in particular the treatment of severe hypoglycemia. The present invention also provides a method of making this powder formulation, and to devices and methods for using the powder formulation.

This invention discloses a pharmaceutical formula for arthritis treatment and/or prevention. The formula contains the following raw materials: a selenium-containing inorganic compound and a zinc-containing inorganic compound. The pharmaceutical formula described herein could be manufactured for topic application and provide a faster and safer treatment for various inflammatory joint pains. Pharmacodynamics results show that the invented pharmaceutical formula can significantly reduce the level of inflammatory cytokines in the joint synovial fluid in arthritis rabbit model, and the formulated ointment can achieve better efficacy compared with Voltaren™ (diclofenac) ointment; therefore the proposed formula has promising clinical application.

A silybin injection contains silybin, sulfobutyl ether-β-cyclodextrin, an organic solvent for injection and may further contain a co-solvent, a lyophilization proppant, a pH regulator, water for injection and the like.

A silybin injection contains silybin, sulfobutyl ether-β-cyclodextrin, an organic solvent for injection and may further contain a co-solvent, a lyophilization proppant, a pH regulator, water for injection and the like.

The present invention provides crystalline forms of efinaconazole, including crystalline efinaconazole forms designated herein as Form A, Form B and Form C, crystalline efinaconazole p-toluenesulfonate salt designated herein as Form I, and processes for their preparation.

The present invention generally relates to homeopathic compositions, and, more particularly, (i) homeopathic compositions comprising a homeopathically potentised form of Passiflora incarnata (Passionflower), and a homeopathically potentised form of Nux Moschata (Nutmeg); or (ii) a homeopathically potentised Carbo Vegetabilis; and a homeopathically potentised Passiflora incarnata; or (iii) a homeopathically potentised Carbo Vegetabilis; and a homeopathically potentised Nux Moschata; and methods of treatment using these homeopathic compositions.

The present invention generally relates to homeopathic compositions, and, more particularly, (i) homeopathic compositions comprising a homeopathically potentised form of Passiflora incarnata (Passionflower), and a homeopathically potentised form of Nux Moschata (Nutmeg); or (ii) a homeopathically potentised Carbo Vegetabilis; and a homeopathically potentised Passiflora incarnata; or (iii) a homeopathically potentised Carbo Vegetabilis; and a homeopathically potentised Nux Moschata; and methods of treatment using these homeopathic compositions.

Provided herein are methods for preparing stable solutions containing 5-methyltetrahydrofolate (MTHF). Also provided herein are stable compositions containing calcium 5-methyltetrahydrofolate (MTHF-Ca).

Provided herein are methods for preparing stable solutions containing 5-methyltetrahydrofolate (MTHF). Also provided herein are stable compositions containing calcium 5-methyltetrahydrofolate (MTHF-Ca).